1
Home
Companies

VYNE Therapeutics

#10119

Rank

$20.16M

Marketcap

US United States

Country

VYNE Therapeutics
Leadership team

Mr. David T. Domzalski (CEO, Pres & Director)

Dr. Iain A. Stuart Ph.D. (Chief Scientific Officer)

Ms. Mutya Harsch J.D. (Gen. Counsel, Chief Legal Officer & Company Sec.)

Products/ Services
Health Care, Pharmaceutical, Therapeutics
Headquarters
Menlo Park, California, United States
Established
2003
Company Registration
SEC CIK number: 0001566044
Revenue
2M - 5M
Traded as
VYNE
Social Media
URL
https://www.vynetherapeutics.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
History

VYNE Therapeutics was established in 2019 and is now a clinical stage company focused on developing and commercializing treatments for skin diseases.

Mission
Our mission is to become the leading provider of innovative treatments for chronic inflammatory skin diseases, creating life-long solutions for patients and enriching lives.
Vision
Our vision is to empower patients with therapies that improve global skin health and reduce the burden of skin diseases.
Key Team

Mr. Tyler Zeronda (CFO, Principal Accounting Officer & Treasurer)

Mr. David Schuz (Sr. VP of Intellectual Property)

Dr. Darrell S. Rigel M.S., M.D., MS (Consultant)

Dr. Russell Elliott D.Phil. (Sr. VP of Pharmaceutical Devel.)

Recognition and Awards
VYNE Therapeutics has received numerous awards, including the 2018 Top Million Dollar Biotech Award, and the 2019 Outstanding New Innovator Award.
References

https://in.investing.com/equities/menlo-therapeutics-inc

https://finance.yahoo.com/quote/VYNE/profile?p=VYNE

https://www.crunchbase.com/organization/menlo-therapeutics

https://companiesmarketcap.com/

https://www.vynetherapeutics.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

VYNE Therapeutics
Leadership team

Mr. David T. Domzalski (CEO, Pres & Director)

Dr. Iain A. Stuart Ph.D. (Chief Scientific Officer)

Ms. Mutya Harsch J.D. (Gen. Counsel, Chief Legal Officer & Company Sec.)

Products/ Services
Health Care, Pharmaceutical, Therapeutics
Headquarters
Menlo Park, California, United States
Established
2003
Company Registration
SEC CIK number: 0001566044
Revenue
2M - 5M
Traded as
VYNE
Social Media
URL
https://www.vynetherapeutics.com